Abstract:Description: Among the two leading causes of death in the United States, each responsible for one in every four deaths, heart disease costs Americans $300 billion, while cancer costs Americans $216 billion per year. They also rank among the top three causes of death in Europe and Asia. In 2012 the University of Michigan Center for Public Health and Community Genomics and Genetic Alliance, with the support of the Centers for Disease Control and Prevention Office of Public Health Genomics, hosted a conference in Atlanta, Georgia to consider related action strategies based on public health genomics. The aim of the conference was consensus building on recommendations to implement genetic screening for three major heritable contributors to these mortality and cost figures: hereditary breast and ovarian cancer (HBOC), familial hypercholesterolemia (FH), and Lynch syndrome (LS). Genetic applications for these three conditions are labeled with a "Tier 1" designation by the U.S. Centers for Disease Control and Prevention because they have been fully validated and clinical practice guidelines based on systematic review support them. Methodology: The conference followed a deliberative sequence starting with nationally recognized clinical and public health presenters for each condition, followed by a Patient and Community Perspectives Panel, working group sessions for each of the conditions, and a final plenary session. The 74 conference participants represented disease research and advocacy, public health, medicine and nursing, genetics, governmental health agencies, and industry. Participants drew on a public health framework interconnecting policy, clinical intervention, surveillance, and educational functions for their deliberations. Results: Participants emphasized the importance of collaboration between clinical, public health, and advocacy groups in implementing Tier 1 genetic screening. Advocacy groups could help with individual and institutional buy-in of Tier 1 programs. Groups differed on funding strategies, with alternative options such as large-scale federal funding and smaller scale, incremental funding solutions proposed. Piggybacking on existing federal breast and colorectal cancer control programs was suggested. Public health departments need to assess what information is now being collected by their state cancer registries. The groups advised that information on cascade screening of relatives be included in toolkits for use by states. Participants stressed incorporation of family history into health department breast cancer screening programs, and clinical HBOC data into state surveillance systems. The carrying out of universal LS screening of tumors in those with colorectal cancer was reviewed. Expansion of universal screening to include endometrial tumors was discussed, as was the application of guidelines recommending cholesterol screening of children 9-11 years old. States more advanced in terms of Tier 1 testing could serve as models and partners with other states launching screening and surveillance programs. A multidisciplinary team of screening program champions was suggested as a means of raising awareness among the consumer and health care communities. Participants offered multiple recommendations regarding use of electronic health records, including flagging of at-risk family members and utilization of state-level health information exchanges. The paper contains an update of policy developments and happenings for all three Tier 1 conditions, as well as identified gaps. Conclusions: Implementation of cascade screening of family members for HBOC and FH, and universal screening for LS in CRC tumors has reached a point of readiness within the U.S., with creative solutions at hand. Facilitating factors such as screening coverage through the Patient Protection and Affordable Care Act, and state health information exchanges can be tapped. Collaboration is needed between public health departments, health care systems, disease advocacy groups, and industry to fully realize Tier 1 genetic screening. State health department and disease networks currently engaged in Tier 1 screening can serve as models for the launch of new initiatives.

Two birds, one stone? The risks and benefits of combined prenatal carrier screening and hereditary cancer screening

Carrier Burden of over 300 Diseases in Han Chinese Identified by Expanded Carrier Testing of 300 Couples Using Assisted Reproductive Technology.

Expanded Preconception Carrier Screening in Clinical Practice: Review of Technology, Guidelines, Implementation Challenges, and Ethical Quandaries

Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities

Expanded Preconception Carrier Screening in Clinical Practice: Review of Technology, Guidelines, Implementation Challenges, and Ethical Quandaries.

Lessons Learned from Expanded Reproductive Carrier Screening in Self‐reported Ashkenazi, Sephardi, and Mizrahi Jewish Patients

A Capillary Electrophoresis-Based Multiplex PCR Assay for Expanded Carrier Screening in the Eastern Han Chinese Population

Clinical application value of pre-pregnancy carrier screening in Chinese Han childbearing population

Genetic Screening—Emerging Issues

Preconception carrier screening and preimplantation genetic testing in the infertility management

A New Paradigm Of Genetic Testing For Hereditary Breast/Ovarian Cancers

Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for all GI Cancers?

Current and future role of genetic screening in gynecologic malignancies

Potential utility of risk stratification for multicancer screening with liquid biopsy tests

Experiences across a genetic screening and testing programme pathway: a qualitative study of mammogram patient perspectives

Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

Expert and Advocacy Group Consensus Findings on the Horizon of Public Health Genetic Testing

Digital cancer genetic risk assessment in a gynecologic oncology clinic.

A Clinical Guide to Hereditary Cancer Panel Testing: Evaluation of Gene-Specific Cancer Associations and Sensitivity of Genetic Testing Criteria in a Cohort of 165,000 High-Risk Patients.

Factors Impacting Intent to Share Multigenic Cancer Testing Results in a Community Hospital Setting